Statistical Sampling: an Underestimated Element of Process Validation?
In a recent FDA Warning Letter, the FDA criticized inadequate process validation for a semi-solid dosage form. What exactly did the FDA find inadequate?
The validation studies were criticized for not reflecting inter- and intra-batch variability. In particular, there was criticism that the sampling was random. The viscosity sampling scheme does not lead to statistical confidence in process performance.
In a second Process Performance Qualification (PPQ) study, the influence of a critical excipient on viscosity was to be shown. Again, the FDA criticized that no inter-batch variability was demonstrated. This is not surprising, since only one run was performed.
As measures, the FDA requires:
- a validation programme, starting with product development, the validation itself and the control/monitoring of the processes with regard to intra- and inter-batch variability
- an equipment and premises qualification programme
- a programme for Process Performance Qualification and Continued Process Verification measures.
You can find the entire Warning Letter on the FDA website.
Related GMP News
26.06.2024End Product Testing versus Process Validation
24.04.2024FDA Requirements for Process Validation
13.03.2024FDA Warning Letter Defines Minimum Criteria for Process Validation
14.02.2024Cloud Computing: Workaround for non-compliant PaaS
07.02.2024Cloud Computing: Validation performed by a CSP on its own - what is the Value?
31.01.2024"Bracketing" during Process Validation